Copyright ©The Author(s) 2016.
World J Diabetes. Aug 25, 2016; 7(16): 333-341
Published online Aug 25, 2016. doi: 10.4239/wjd.v7.i16.333
Table 1 The drugs under current development for the treatment of diabetic macular edema
DrugStudy designResults
Danazol23 eyes: 12-wk placebo-controlSignificant decreases in CRT (-86% vs -29%) and macular volume (P = 0.05)
Improvement in BCVA by 1 category (14% vs 47%)
Minocylcine5 eyes: Minocycline 100 mg BID for 6 moImproved BCVA and CRT compared to historic
Loteprednol etabonate (topical)20 eyes: Single masked, 2-dose, randomized trialPhase II clinical trial (KPI-121-C-004) underway
Dexamethasone phosphateIontophoresis driven into the eye EGP-437Positive results in 15 patients
PAN-908064 monotherapy arms in phase I/II trialMaintenance therapy after single anti-VEGF injections
Diclofenac57 eyes: Intravitreal diclofenac vs bevacizumabDiclofenac achieved better improvement in BCVA compared to bevacizumab (Δ -0.08 LogMAR vsΔ +0.04 LogMAR, P = 0.033)
Bevacizumab improved macular edema slightly
SirolimusPhase I trial: Dose- escalating, subconjunctival of intravitreal injectionsSubconjunctival: median increase in BCVA was +4.0 letters at 45 d
Intravitreal: Median increase in BCVA was +4.0 letters at 90 d
FasudilSingle intravitreal injections of fasudil with bevacizumabAt 4 wk ΔBCVA (0.84 ± 0.35 LogMAR to 0.49 ± 0.29 LogMAR; P = 0.003) and mean ΔCRT (448 ± 123 μm to 347 ± 76 μm; P = 0.001)
Luminate (ALG-001)Phase IIb DME trial (targets integrin receptors)Data expected third quarter of 2016
Plasma kallekrein inhibitor (KVD001)Phase II trials: Monotherapy for resistant DME combined with anti-VEGFPhase I trial demonstrated safety after intravitreal injections
REGN910 (Ang 2 Ab)Phase I trialCompleted. Now planning phase II trials for nAMD and DME